NCT02020070View on ClinicalTrials.gov

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 18, 2013

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Metastatic Castration Sensitive Prostate Cancer
Interventions
DRUG

Degarelix

DRUG

Ipilimumab

PROCEDURE

Radical Prostatectomy

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Ferring Pharmaceuticals
All Listed Sponsors
collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER